导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.08% | 3351/4773 |
| 近一周 | -1.67% | 638/5462 |
| 近一月 | 0.43% | 600/5421 |
| 近一季 | -0.32% | 807/5209 |
| 近半年 | -9.77% | 3549/4920 |
| 近一年 | -3.29% | 3051/4366 |
| 近两年 | 25.79% | 2461/2954 |
| 近三年 | 17.22% | 1575/2253 |
| 成立以来 | 66.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.30% 2228/4961 |
-10.64% 4143/5312 |
- - |
- - |
| 2025 | 7.12% 2935/4813 |
-4.79% 3224/3635 |
2.43% 1569/4076 |
7.27% 3463/4524 |
2.40% 965/4813 |
| 2024 | 25.23% 268/3463 |
9.07% 150/2808 |
2.51% 347/3014 |
11.48% 2514/3129 |
0.47% 1206/3463 |
| 2023 | -1.40% 509/2656 |
6.42% 688/2280 |
-1.09% 443/2385 |
0.70% 351/2515 |
-6.97% 2000/2655 |
| 2022 | -9.75% 185/2207 |
-5.41% 190/1919 |
1.70% 1435/2016 |
-9.51% 285/2113 |
3.67% 658/2208 |
| 2021 | 10.34% 434/1822 |
1.83% 240/1255 |
-0.13% 1128/1330 |
7.54% 182/1466 |
0.88% 1047/1822 |
| 2020 | 16.09% 777/1250 |
-9.67% 706/1028 |
2.51% 969/1067 |
16.05% 174/1164 |
8.03% 690/1184 |
| 2019 | 21.03% 657/1092 |
19.04% 636/739 |
-3.11% 370/788 |
-1.45% 658/850 |
6.49% 601/918 |
| 2018 | -21.81% 222/834 |
- - |
-8.50% 224/631 |
1.64% 132/660 |
-9.74% 161/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方小康ETF联接C VS. 长安沪深300非周期A(740101) |